Dataset Information


Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States.

ABSTRACT: In the United States, non-alcoholic fatty liver disease (NAFLD) is the most common liver disease and associated with higher mortality according to data from earlier National Health and Nutrition Examination Survey (NHANES) 1988-1994. Our goal was to determine the NAFLD prevalence in the recent 1999-2012 NHANES, risk factors for advanced fibrosis (stage 3-4) and mortality. NAFLD was defined as having a United States Fatty Liver Index (USFLI) > 30 in the absence of heavy alcohol use and other known liver diseases. The probability of low/high risk of having advanced fibrosis was determined by the NAFLD Fibrosis Score (NFS). In total, 6000 persons were included; of which, 30.0% had NAFLD and 10.3% of these had advanced fibrosis. Five and eight-year overall mortality in NAFLD subjects with advanced fibrosis was significantly higher than subjects without NAFLD ((18% and 35% vs. 2.6% and 5.5%, respectively) but not NAFLD subjects without advanced fibrosis (1.1% and 2.8%, respectively). NAFLD with advanced fibrosis (but not those without) is an independent predictor for mortality on multivariate analysis (HR = 3.13, 95% CI 1.93-5.08, p<0.001). In conclusion, in this most recent NHANES, NAFLD prevalence remains at 30% with 10.3% of these having advanced fibrosis. NAFLD per se was not a risk factor for increased mortality, but NAFLD with advanced fibrosis was. Mexican American ethnicity was a significant risk factor for NAFLD but not for advanced fibrosis or increased mortality.


PROVIDER: S-EPMC5367688 | BioStudies | 2017-01-01

REPOSITORIES: biostudies

Similar Datasets

2013-08-30 | E-GEOD-49541 | ArrayExpress
2020-01-01 | S-EPMC6995480 | BioStudies
2020-01-01 | S-EPMC7090310 | BioStudies
2020-01-01 | S-EPMC7446805 | BioStudies
2020-01-01 | S-EPMC7591518 | BioStudies
2019-01-01 | S-EPMC6380844 | BioStudies
2015-01-01 | S-EPMC4646649 | BioStudies
| S-DIXA-D-1160 | BioStudies
| S-EPMC7515788 | BioStudies
2021-01-01 | S-EPMC7914565 | BioStudies